A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

• Status: Active, not recruiting
• Trial end date: 2022-01-12
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Male or female

• 3 months of age and older

• Confirmed diagnosis of atopic dermatitis according to Hanifin and Rajka criteria

• Minimum of 5% BSA affected by atopic dermatitis

• ISGA score of Mild (2) or Moderate (3)

Exclusion Criteria:

• Has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome).